ScholarIQanswers from OpenAlex

Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis

PaperCitations, authors & open-access status

Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis have?

ScholarIQcitation count

Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis has 3 citations in the OpenAlex counts ScholarIQ stores.

When was Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis published?

ScholarIQyear

Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis has 2025 year in the ScholarIQ index.

What is the open-access status of Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis?

ScholarIQoa status

Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis has gold oa status in the ScholarIQ index.

What is the DOI of Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis?

ScholarIQdoi

The DOI for Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis is on the source record.

What is the PMID of Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis?

ScholarIQpmid

The PMID for Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis is on the source record.

What is the OpenAlex record for Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis?

ScholarIQopenalex

The OpenAlex for Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial